Intelligently
mining the market

Investors + news

Eagle Pharmaceuticals 2021 Annual Report

Investors

Featured Press Release

WOODCLIFF LAKE, N.J., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will participate in a panel presentation at the Cantor Global
See More
-- CAL02 is a unique therapeutic agent that is designed to work differently from antibiotics, aiming to disarm an infectious pathogen’s virulence factors to reduce damage and mitigate disease -- -- The first-in-human study showed positive safety and efficacy when added to standard of care in
See More
-- Abstract compares relative effects on cognitive function following sedation with Byfavo (remimazolam) for injection versus midazolam WOODCLIFF LAKE, N.J., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has been
See More

Upcoming Events & Presentations